Targeting tumours with genetically enhanced T lymphocytes

The genetic modification of T lymphocytes is an important approach to investigating normal T-cell biology and to increasing antitumour immunity. A number of genetic strategies aim to increase the recognition of tumour antigens, enhance antitumour activities and prevent T-cell malfunction. T cells can also be engineered to increase safety, as well as to express markers that can be tracked by non-invasive imaging technologies. Genetically modified T cells are therefore proving to be of great value for basic immunology and experimental immunotherapy.

[1]  P. Levine.  A survey of the significance of the Rh factor. , 1948, Blood.

[2]  Melvin Cohn,et al.  A Theory of Self-Nonself Discrimination , 1970, Science.

[3]  J. McCubrey,et al.  Transfer of specificity by murine alpha and beta T-cell receptor genes. , 1986, Nature.

[4]  T. Taniguchi,et al.  Retroviral expression of the human IL‐2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. , 1987, The EMBO journal.

[5]  R. Schwartz,et al.  Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo , 1987, The Journal of experimental medicine.

[6]  D. Longo,et al.  Cancer chemotherapy and biological response modifiers annual , 1987 .

[7]  C. Thompson,et al.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. , 1989, Science.

[8]  H. Karasuyama,et al.  Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene , 1989, The Journal of experimental medicine.

[9]  C. Melief,et al.  Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens , 1989, The Journal of experimental medicine.

[10]  B. Seed,et al.  Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides , 1991, Cell.

[11]  M. Jenkins,et al.  CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. , 1991, Journal of immunology.

[12]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[13]  Arthur Weiss,et al.  The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.

[14]  G. Crabtree,et al.  Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. , 1991, Science.

[15]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R Wieser,et al.  Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region , 1993, Molecular and cellular biology.

[17]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[18]  Y. Yarden,et al.  Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. , 1993, Journal of immunology.

[19]  J. Gribben,et al.  B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance , 1993, The Journal of experimental medicine.

[20]  W. Anderson,et al.  Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. , 1993, Journal of immunology.

[21]  A. Houghton.  Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.

[22]  S. Rosenberg,et al.  The Use of Gene‐Modified Tumor‐Infiltrating Lymphocytes for Cancer Therapy , 1994, Annals of the New York Academy of Sciences.

[23]  M. Croft,et al.  Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. , 1994, Journal of immunology.

[24]  C. Bordignon,et al.  Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. , 1994, Blood.

[25]  D. Hafler,et al.  Functional three-domain single-chain T-cell receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Massagué,et al.  Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex , 1995, Molecular and cellular biology.

[27]  R. Karr,et al.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.

[28]  S. Rosenberg,et al.  Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. , 1995, Blood.

[29]  R. Morgan,et al.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Sercarz,et al.  Induction of anti-self-immunity to cure cancer , 1995, Cell.

[31]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[32]  B. Groner,et al.  A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. , 1995, Gene therapy.

[33]  S. Rosenberg,et al.  In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. , 1995, Cancer research.

[34]  H. Maeda,et al.  TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. , 1996, Journal of immunology.

[35]  B. Groner,et al.  Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  L. Álvarez-Vallina,et al.  Antigen‐specific targeting of CD28‐mediated T cell co‐stimulation using chimeric single‐chain antibody variable fragment‐CD28 receptors , 1996, European journal of immunology.

[37]  M. Weijtens,et al.  Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. , 1996, Journal of immunology.

[38]  Antonio Lanzavecchia,et al.  T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.

[39]  M. Sadelain,et al.  The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes , 1997, Gene Therapy.

[40]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[41]  B. Groner,et al.  Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. , 1997, Journal of immunology.

[42]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[43]  M. Sadelain,et al.  Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. , 1997, Blood.

[44]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[45]  D. Longo,et al.  Sequential development of structural and functional alterations in T cells from tumor-bearing mice. , 1997, Journal of immunology.

[46]  M. Sadelain,et al.  Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes , 1998, The Journal of experimental medicine.

[47]  M. Davis,et al.  A receptor/cytoskeletal movement triggered by costimulation during T cell activation. , 1998, Science.

[48]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[49]  A. Wu,et al.  CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  S. Canevari,et al.  Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. , 1998, Cancer gene therapy.

[51]  S. Rosenberg,et al.  A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen , 1998, Nature Medicine.

[52]  C. June,et al.  Costimulatory approaches to adoptive immunotherapy. , 1998, Current opinion in oncology.

[53]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Reddish,et al.  Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 , 1998, Nature Medicine.

[55]  A. Lawson,et al.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. , 1998, Journal of immunology.

[56]  B. V. van Krimpen,et al.  Chimeric scFv/γ receptor‐mediated T‐cell lysis of tumor cells is coregulated by adhesion and accessory molecules , 1998, International journal of cancer.

[57]  D. E. Anderson,et al.  Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. , 1998, Journal of immunology.

[58]  A. Sharpe,et al.  The role of B7 co‐stimulation in activation and differentiation ofCD4+and CD8+T cells , 1998, Immunological reviews.

[59]  J. Humm,et al.  Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. , 1998, Cancer research.

[60]  M. Marić,et al.  Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells. , 1998, Cancer research.

[61]  R. Blasberg,et al.  Imaging Transgene Expression for Gene Therapy , 1999, Journal of clinical pharmacology.

[62]  D. Klatzmann,et al.  Suicide gene-mediated modulation of graft-versus-host disease. , 1999, Leukemia & lymphoma.

[63]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Germain,et al.  The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. , 1999, Annual review of immunology.

[65]  N. Mitsiades,et al.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.

[66]  M. Sadelain,et al.  Activation conditions determine susceptibility of murine primary T‐lymphocytes to retroviral infection , 1999, The journal of gene medicine.

[67]  H. Hamada,et al.  Overexpression of CD82 on human T cells enhances LFA‐1 / ICAM‐1‐mediated cell‐cell adhesion: functional association between CD82 and LFA‐1 in T cell activation , 1999, European journal of immunology.

[68]  A. Lanzavecchia,et al.  T lymphocyte costimulation mediated by reorganization of membrane microdomains. , 1999, Science.

[69]  J. Mcarthur,et al.  Impact of chimeric immune receptor extracellular protein domains on T cell function , 1999, Gene Therapy.

[70]  R. Flavell,et al.  The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. , 1999, Journal of immunology.

[71]  C. Yun,et al.  Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  P. Hand,et al.  Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. , 1999, Human gene therapy.

[73]  N. Bander,et al.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. , 1999, Neoplasia.

[74]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[75]  M. Weijtens,et al.  Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production , 2000, Gene Therapy.

[76]  C. Yun,et al.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. , 2000, Neoplasia.

[77]  D. Scadden,et al.  Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. , 2000, Blood.

[78]  G. Hayman,et al.  Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. , 2000, Human gene therapy.

[79]  J. Mcarthur,et al.  Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. , 2000, Journal of immunotherapy.

[80]  A. Abbas,et al.  Functional Responses and Costimulator Dependence of Memory CD4+ T Cells1 , 2000, The Journal of Immunology.

[81]  T. Kitamura,et al.  Functional Reconstitution of Class II MHC-Restricted T Cell Immunity Mediated by Retroviral Transfer of the αβ TCR Complex1 , 2000, The Journal of Immunology.

[82]  S. Rosenberg,et al.  Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. , 2000, Human gene therapy.

[83]  J. Trapani,et al.  Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL1 , 2000, The Journal of Immunology.

[84]  G. Korbutt,et al.  Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is a Death Receptor for Granzyme B during Cytotoxic T Cell–Induced Apoptosis , 2000, Cell.

[85]  J. Mcarthur,et al.  Anti-Tumor CC49-ζ CD4 T Cells Possess Both Cytolytic and Helper Functions , 2000 .

[86]  J W Gratama,et al.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.

[87]  J. Lebkowski,et al.  Ligand-mediated cytolysis of tumor cells: Use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes , 2000, Cancer Gene Therapy.

[88]  S. Larson,et al.  Imaging transgene expression with radionuclide imaging technologies. , 2000, Neoplasia.

[89]  T. Kitamura,et al.  Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. , 2000, Journal of immunology.

[90]  E. Beecham,et al.  Coupling CD28 Co-Stimulation to Immunoglobulin T-Cell Receptor Molecules: The Dynamics of T-Cell Proliferation and Death , 2000, Journal of immunotherapy.

[91]  P. Hwu,et al.  Recognition of human colon cancer by T cells transduced with a chimeric receptor gene , 2000, Cancer Gene Therapy.

[92]  E. Beecham,et al.  Dynamics of Tumor Cell Killing by Human T Lymphocytes Armed With an Anti-Carcinoembryonic Antigen Chimeric Immunoglobulin T-Cell Receptor , 2000, Journal of immunotherapy.

[93]  M. Sadelain,et al.  Retroviral-mediated gene transfer in primary murine and human T-lymphocytes , 2000, Molecular biotechnology.

[94]  V. Diehl,et al.  An entirely humanized CD3 ζ‐chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen–positive tumor cells , 2000, International journal of cancer.

[95]  P. Hwu,et al.  Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. , 2000, Human gene therapy.

[96]  J. Muche,et al.  T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells , 2001, Gene Therapy.

[97]  B. Pasche.  Role of transforming growth factor beta in cancer , 2001, Journal of cellular physiology.

[98]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[99]  J. Trapani,et al.  Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. , 2001, Journal of immunology.

[100]  Mark J. Smyth,et al.  Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs FcεRI-γ1 , 2001, The Journal of Immunology.

[101]  T. Geiger,et al.  Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. , 2001, Transfusion medicine reviews.

[102]  T. Schumacher,et al.  Immunotherapy through TCR gene transfer , 2001, Nature Immunology.

[103]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[104]  C. Contag,et al.  Bioluminescence imaging of lymphocyte trafficking in vivo. , 2001, Experimental hematology.

[105]  W. Heath,et al.  Cross-presentation, dendritic cells, tolerance and immunity. , 2001, Annual review of immunology.

[106]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.

[107]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[108]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[109]  R. Flavell,et al.  Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. , 2001, Blood.

[110]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[111]  R. Offringa,et al.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[112]  M. Kattan,et al.  Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Craig W. Reynolds,et al.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.

[114]  B. Seliger,et al.  T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. , 2001, Cancer research.

[115]  G. Nolan,et al.  Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. , 2001, Clinical immunology.

[116]  S. Larson,et al.  Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. , 2001, Neoplasia.

[117]  A. Sharpe,et al.  Rejection of Mouse Cardiac Allografts by Costimulation in trans1 , 2001, The Journal of Immunology.

[118]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[119]  J. Trapani,et al.  Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. , 2002, Blood.

[120]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[121]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[122]  G. Hayman,et al.  Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. , 2002, Cancer immunology, immunotherapy : CII.

[123]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[124]  L. Ren-Heidenreich,et al.  Comparison of the TCR ζ-chain with the FcR γ-chain in chimeric TCR constructs for T cell activation and apoptosis , 2002, Cancer Immunology, Immunotherapy.

[125]  R. Weissleder,et al.  In vivo imaging of gene delivery and expression , 2002 .

[126]  M. Sadelain,et al.  Sturm und drang over suicidal lymphocytes. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  J. Massagué,et al.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. , 2002, Blood.

[128]  D. Green,et al.  Lymphocyte apoptosis: refining the paths to perdition. , 2002, Current opinion in hematology.

[129]  R. Mulligan,et al.  Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[130]  D. Baltimore,et al.  Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[131]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[132]  C. Rooney,et al.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.

[133]  V. Engelhard,et al.  Antigens derived from melanocyte differentiation proteins: self‐tolerance, autoimmunity, and use for cancer immunotherapy , 2002, Immunological reviews.

[134]  S. Riddell,et al.  Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. , 2003, Blood.

[135]  Michel Sadelain,et al.  Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes , 2003, Nature Biotechnology.

[136]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated into One Combined CD28/CD3ζ Signaling Receptor Molecule , 2004, The Journal of Immunology.